(2S)-2-amino-3-(3,4-bis(((R)-2-(benzoyloxy)propanoyl)oxy)phenyl)propanoic acid hydrochloride | 1379614-03-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-amino-3-(3,4-bis(((R)-2-(benzoyloxy)propanoyl)oxy)phenyl)propanoic acid hydrochloride
• 英文别名: (2S)-2-amino-3-[3,4-bis[[(2R)-2-benzoyloxypropanoyl]oxy]phenyl]propanoic acid;hydrochloride
• CAS: 1379614-03-5
• 化学式: C₂₉H₂₇NO₁₀*ClH
• 分子量: 585.995
• InChiKey: FKSRENSSJUUXQI-KJGMQWEMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.36
• 重原子数：
  41
• 可旋转键数：
  15
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  169
• 氢给体数：
  3
• 氢受体数：
  11

文献信息

• NOVEL COMPOUND AND MEDICAL USE THEREOF
  申请人：Kokubo Masaya

  公开号：US20130245074A1

  公开（公告）日：2013-09-19

  Provided is a levodopa prodrug that overcomes the problems attributed to the blood kinetics of levodopa such as large number of doses and the incidence of side effects due to frequent dosing. (2S)-2-Amino-3-(3,4-bis((2-(benzoyloxy)-2-methylpropanoyl)oxy)phenyl)propanoic acid, a salt thereof, or a solvate thereof is a levodopa prodrug, and provides a flat blood concentration-time profile of levodopa through oral administration, and therefore is useful as a preventive and/or therapeutic agent for Parkinson's disease and/or Parkinson's syndrome that overcomes the problems associated with pharmaceutical preparations of levodopa.

  提供了一种左多巴前药，它克服了左多巴的血液动力学问题，例如需要大量剂量和频繁给药导致的副作用。其化学名为(2S)-2-氨基-3-(3,4-双((2-(苯甲酰氧基)-2-甲基丙酰氧)苯基)丙酸，其盐或溶剂化合物是左多巴前药，通过口服给药提供了左多巴平稳的血药浓度时间曲线，因此可用作克服左多巴药物制剂相关问题的帕金森病和/或帕金森综合征的预防和/或治疗药物。
• TOPICAL COMPOSITIONS
  申请人：GREEN Monique Renata

  公开号：US20130243707A1

  公开（公告）日：2013-09-19

  Topical compositions are disclosed that are useful for delivering a therapeutic level of an NSAID to a target within a subject having a local inflammatory disorder. A composition of the present invention comprises a Drug and a solvent system, wherein the solvent system comprises at least two solvent alcohols and wherein the solvent system is present in an amount sufficient to solubilize the Drug, the solvent system is a low alkanol system, and the composition is a single phase composition. Exemplary solvent systems are those for which one of the at least two solvent alcohols is polyethylene glycol, glycerin, butylene glycol, diproylene glycol, propylene glycol, ethanol, isopropanol, or a derivative thereof. Optionally the local inflammatory disorder is pseudofolliculitis barbae, dermatitis, psoriasis, wounds, or sunburn.
• US8748485B2
  申请人：——

  公开号：US8748485B2

  公开（公告）日：2014-06-10
• US8703816B2
  申请人：——

  公开号：US8703816B2

  公开（公告）日：2014-04-22